{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T05:06:05Z","timestamp":1772255165808,"version":"3.50.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1097\/mcg.0000000000000042","type":"journal-article","created":{"date-parts":[[2014,1,17]],"date-time":"2014-01-17T08:39:15Z","timestamp":1389947955000},"page":"866-869","source":"Crossref","is-referenced-by-count":14,"title":["Calprotectin in Bile"],"prefix":"10.1097","volume":"48","author":[{"given":"Torsten","family":"Voigtl\u00e4nder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Wlecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed A.","family":"Negm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrike","family":"Lenzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim O.","family":"Lankisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-13-20210201","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bpg.2011.10.003","article-title":"Medical and endoscopic therapy of primary sclerosing cholangitis.","volume":"25","author":"Weismuller","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R3-13-20210201","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/liv.12028","article-title":". Non-IBD immunological diseases are a risk factor for reduced survival in PSC.","volume":"33","author":"Rupp","year":"2013","journal-title":"Liver Int"},{"key":"R4-13-20210201","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00535-002-1126-z","article-title":". Early gallbladder carcinoma associated with primary sclerosing cholangitis and ulcerative colitis.","volume":"38","author":"Yamamoto","year":"2003","journal-title":"J Gastroenterol"},{"key":"R5-13-20210201","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.bpg.2011.10.002","article-title":"Primary sclerosing cholangitis and malignancy.","volume":"25","author":"Boberg","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R6-13-20210201","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1478-3231.2011.02614.x","article-title":"Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort.","volume":"32","author":"de Valle","year":"2012","journal-title":"Liver Int"},{"key":"R7-13-20210201","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1002\/ibd.22917","article-title":". Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.","volume":"18","author":"DHaens","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R8-13-20210201","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MIB.0b013e3182810066","article-title":". Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes.","volume":"19","author":"Schoepfer","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R9-13-20210201","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/hep.23099","article-title":". S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis.","volume":"50","author":"Nemeth","year":"2009","journal-title":"Hepatology"},{"key":"R10-13-20210201","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.bcp.2006.05.017","article-title":". S100A8 and S100A9 in inflammation and cancer.","volume":"72","author":"Gebhardt","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"R11-13-20210201","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1189\/jlb.1008647","article-title":". The endogenous Toll-like receptor 4 agonist S100A8S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer.","volume":"86","author":"Ehrchen","year":"2009","journal-title":"J Leukoc Biol"},{"key":"R12-13-20210201","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/ijc.27591","article-title":". Hypoxia and HIF-1 increase S100A8 and S100A9 expression in prostate cancer.","volume":"131","author":"Grebhardt","year":"2012","journal-title":"Int J Cancer"},{"key":"R13-13-20210201","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3899\/jrheum.120079","article-title":". Serum S100A8A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Stills disease.","volume":"39","author":"Kim","year":"2012","journal-title":"J Rheumatol"},{"key":"R14-13-20210201","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3899\/jrheum.091120","article-title":". Serum calprotectin as a marker for disease activity and severity in adult-onset Stills disease.","volume":"37","author":"Jung","year":"2010","journal-title":"J Rheumatol"},{"key":"R15-13-20210201","doi-asserted-by":"crossref","first-page":"e29821","DOI":"10.1371\/journal.pone.0029821","article-title":". S100A9 is a biliary protein marker of disease activity in primary sclerosing cholangitis.","volume":"7","author":"Reinhard","year":"2012","journal-title":"PLoS One"},{"key":"R16-13-20210201","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2011-200598","article-title":". The Toll-like receptor 4 agonist MRP814 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis.","volume":"71","author":"Holzinger","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R17-13-20210201","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s00535-007-2086-0","article-title":". Fecal calprotectin and elastase 1 determinations in patients with pancreatic diseases: a possible link between pancreatic insufficiency and intestinal inflammation.","volume":"42","author":"Pezzilli","year":"2007","journal-title":"J Gastroenterol"},{"key":"R18-13-20210201","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0025-6196(11)64614-4","article-title":". A revised natural history model for primary sclerosing cholangitis.","volume":"75","author":"Kim","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"R19-13-20210201","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.gie.2010.02.043","article-title":". Routine bile collection for microbiological analysis during cholangiography and its impact on the management of cholangitis.","volume":"72","author":"Negm","year":"2010","journal-title":"Gastrointest Endosc"},{"key":"R20-13-20210201","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1586\/egh.12.80","article-title":"Primary sclerosing cholangitis: a review and update on therapeutic developments.","volume":"7","author":"Tabibian","year":"2013","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R21-13-20210201","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.cgh.2013.02.016","article-title":"Primary Sclerosing CholangitisDiagnosis, Prognosis and Management.","volume":"11","author":"Singh","year":"2013","journal-title":"Clin Gastroenterology Hepatol"},{"key":"R22-13-20210201","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0168-8278(01)00288-4","article-title":". Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.","volume":"36","author":"Bergquist","year":"2002","journal-title":"J Hepatol"},{"key":"R23-13-20210201","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1053\/j.gastro.2010.09.004","article-title":"Pathogenesis of cholestatic liver disease and therapeutic approaches.","volume":"139","author":"Hirschfield","year":"2010","journal-title":"Gastroenterology"},{"key":"R24-13-20210201","doi-asserted-by":"crossref","first-page":"G1077","DOI":"10.1152\/ajpgi.00227.2012","article-title":"Advances in cholangiocyte immunobiology.","volume":"303","author":"Syal","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R25-13-20210201","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/hep.24103","article-title":". Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis.","volume":"53","author":"Lankisch","year":"2011","journal-title":"Hepatology"},{"key":"R26-13-20210201","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2012.10.013","article-title":". Improvement of serum alkaline phosphatase to 1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis.","volume":"58","author":"Al Mamari","year":"2013","journal-title":"J Hepatol"},{"key":"R27-13-20210201","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cgh.2012.12.032","article-title":". Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.","volume":"11","author":"Lindstrom","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R28-13-20210201","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF02977781","article-title":"Roles of calcium-binding proteins, S100A8 and S100A9, in invasive phenotype of human gastric cancer cells.","volume":"30","author":"Yong","year":"2007","journal-title":"Arch Pharm Res"},{"key":"R29-13-20210201","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2174\/156800908784533445","article-title":". S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast.","volume":"8","author":"Arai","year":"2008","journal-title":"Curr Cancer Drug Targets"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCG.0000000000000042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T08:28:46Z","timestamp":1716452926000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004836-201411000-00013"}},"subtitle":["A Disease Severity Marker in Patients With Primary Sclerosing Cholangitis"],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0000000000000042","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}